FMO5 and chronic granulomatous disease: Humans with chronic granulomatous disease, characterized by loss of NADPH oxidase activity, have a 40–55% lifetime risk of infection with A. fumigatus despite universal exposure, suggesting the existence of NADPH oxidase-independent effectors (7).